FDA Approval: 1L Durvalumab + Tremelimumab + Chemotherapy for NSCLC
Podcast | English | 33 Min
Image For Activity Cover
Credit
No Credit Offered
Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first-line treatment in patients with metastatic non small-cell lung cancer (NSCLC).

Podcast Hosts:

  • Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  

Podcast Guests: 

  • Tejas Patil, MD, Assistant Professor, University of Colorado Cancer Center, Aurora, CO
Powered By